Logo

SSC and PAH

What is PAH?

A subtype of pulmonary hypertension (PH)

Pulmonary arterial hypertension (PAH) is a rare, progressive disease characterised by elevated pulmonary arterial pressure and vascular resistance that eventually leads to right ventricular failure and death[1]

Early identification and intervention are key to changing the course of the disease[2]

PAH is a severe and often fatal complication of CTD:[3]

  • It is most commonly seen in SSc, accounting for 75% of CTD-PAH cases[4]
  • Approximately 1 in 10 patients with SSc are estimated to have PAH[5]

PAH is a leading cause of death in patients with SSc, accounting for >50% of deaths in SSc-PAH patients[6]

What is PAH? - Different subcategories

Adapted from Badesch et al. 2010[7]

Component not published? componentType is undefined.

Contact

Want to know more? Contact our medical team!

MATHIJS KRUK

Medical Scientific Liaison Pulmonary
Hypertension NL
+31 6 1238 17 11
mkruk1@its.jnj.com

ROB JANSSEN, PHD

Medical Advisor Pulmonary
Hypertension NL
+31 6 53 72 73 03
rjansse9@its.jnj.com

Contactez-nous

Vous avez une question à nous poser ou vous n’avez pas trouvé ce que vous recherchiez ? Contactez-nous, nous serons ravis de vous aider.

Découvrez nos produits

Découvrez le portefeuille de produits Janssen et les résumés des caractéristiques des produits correspondants.

Visualisez les images 3D de la maladie

Découvrez les animations 3D interactives de l’anatomie humaine et de différentes pathologies.

Abbreviations

ALT, alanine aminotransferase; AST, aspartate aminotransferase;CHD, congenital heart disease; CI, confidence interval; CTD, connective tissue disease; ERA, endothelin receptor antagonist; ERS, European Respiratory Society; ESC, European Society of Cardiology; HIV, human immunodeficiency virus; HPAH, heritable pulmonary arterial hypertension; HR, hazard ratio; IPAH, idiopathic pulmonary arterial hypertension; LFT, liver function test; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PoPH, portopulmonary hypertension; RHC, right heart catheterisation; SSc, systemic sclerosis; TRV, tricuspid regurgitation velocity; ULN, upper limit of normal; 6MWD, six-minute walk distance

References

Galiè N, et al. Eur Heart J 2010; 31(17):2080–2086
National Pulmonary Hypertension Centres of the UK and Ireland Heart 2008; 94:i1–i41
Rhee RL, et al. Am J Respir Crit Care 2015; 192(9):1111–1117
Zanatta E, et al. Exp Biol Med (Maywood) 2019; 244(2):120–131
Kiely DG, et al. Eur Heart J 2019; 21(Suppl K):K9–20
Kolstad KD, et al. Chest 2018; 154(4):862–871
Badesch DB, et al. Chest 2010; 137(2):376–387
CP-192318 - November 2020